Compare Amphastar Pharmaceuticals Inc (AMPH) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Capri Holdings Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Capri Holdings Ltd trades at $18.04 (market cap $2.07B). The key difference: Capri Holdings Ltd is far larger — about 2.5× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | CPRI | |
|---|---|---|
Market Cap | $826.08M | $2.07B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $27.66 |
52-Week Low | $16.87 | $16.79 |
Enterprise Value | $1.22B | $3.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CPRI trades at $18.04, down 0.22% with bearish technical signals. The company reported mixed Q4 2026 results with an EPS beat but revenue challenges, while showing a net loss of $1.18 billion in 2025. Analyst consensus is divided with a $23.33 price target, and recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo brands.
The outlook hinges on successful execution of brand revamps and cost controls. Key risks include luxury demand volatility and high debt, but current valuation metrics like P/S of 0.62 may offer value if the turnaround gains traction. Institutional sentiment is cautiously optimistic with 44% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
